Showing 1-10 of about 105 articles.
Translate Bio, Inc.
LEXINGTON, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio, Inc.
-- Initiated multiple-ascending dose portion of the Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis -- -- Received FDA communication related to previously announced IND clinical...
MaRS Innovation
Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific...
AzurRx BioPharma, Inc.
First site initiated at the Cystic Fibrosis InstituteInitial top line data expected in 2019 NEW YORK, Dec. 19, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the...
InSphero AG
Schlieren, Switzerland, Dec. 19, 2018 (GLOBE NEWSWIRE) -- InSphero AG and Path BioAnalytics today announced a partnership through which Path BioAnalytics will produce and test 3D cystic fibrosis...
Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemLenabasum in late-stage clinical studies in three orphan...
Claire's Place Foundation
Los Angeles, CA, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is proud to...
AzurRx BioPharma, Inc.
NEW YORK, Dec. 12, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies...
Translate Bio, Inc.
Continued progress with ongoing Phase 1/2 clinical trial in CF and towards IND submission for OTC Deficiency LEXINGTON, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a...
Translate Bio, Inc.
LEXINGTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Showing 1-10 of about 105 articles.
